This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.
This statement relates to a field safety notice released by intrauterine device manufacturer Eurogine in 2018 and 2019.
FSRH statement: Thrombosis with thrombocytopenia, AstraZeneca COVID-19 vaccination and combined hormonal contraception May 2021
Guidance developed by FSRH's Clinical Effectiveness Unit (CEU) following updated advice by the Joint Committee on Vaccination and Immunisation (JCVI) on vaccination with the Oxford/AstraZeneca COVID-19 vaccine.
Sexually active women of reproductive age with eating disorders require effective contraception despite the fact that amenorrhoea and anovulation are common in this population. This statement provides clinicians with a resource for best helping women with eating disorders choose the most appropriate and acceptable contraception for them. Download and save the document here.
Matrix of Annual Expectation of Educational Progression ST1 to 6 in Community Sexual and Reproductive Health - March 2021 for ARCP in COVID-19 period and beyond.
FSRH response to Government consultation on the reform of the national Public Health System April 2021
FSRH response to consultation ‘Transforming the public health system: reforming the public health system for the challenges of our times’ by the Department of Health and Social Care (DHSC).
Read about our FSRH international strategy, presented by Dr Nicky Morgan at our international strategy launch event on 28 April 2021.
Download the agenda for our GTPD & FRT Virtual Event, which took place on 27 April 2021.
Download a useful list of resources, including web links, videos and content you can use when training.
A certificate for attendees of the International Strategy launch webinar, that took place on Wednesday 28 April, 2021
Guide to Applying for the CESR